##plugins.themes.academic_pro.article.sidebar##

Download
pdf

##plugins.themes.academic_pro.article.main##

Abstract

The corona virus as mentioned as SARS-Cov2 is a respiratory disease that causes a respiratory diseases and main responsible for the pandemic of corona in 2019 which started in Wuhan city- China and dispersed to the worldwide cases a million of infection among people in different countries, this study to showed the relationship between the patient infected previously with SARS-CoV2 and the possible infection to Hepatitis virus type C, the main causes of acute hepatitis. The patients tested from AL Yarmouk Hospital- Baghdad and ranged between 19-74 years old from both genders. The result showed no susceptible infection between the HCV disease and previous infection with corona disease.

Keywords

infection HCV disease Hepatitis C

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Hasanain Sahib Salih, Shatha M Ali Safar, & Safa Tawfeeq Whaeeb. (2023). Study the susceptibility of infection with Hepatitis type C for Covid – 19 patients in Baghdad District – Iraq. Texas Journal of Agriculture and Biological Sciences, 15, 67–78. Retrieved from https://zienjournals.com/index.php/tjabs/article/view/3789

References

  1. https://www.euro.who.int
  2. -Page J, Hinshaw D, McKay B (26 February 2021). "In Hunt for Covid-19 Origin, Patient Zero Points to Second Wuhan Market – The man with the first confirmed infection of the new coronavirus told the WHO team that his parents had shopped there". The Wall Street Journal. Retrieved 27 February 2021.
  3. -"New coronavirus stable for hours on surfaces". National Institutes of Health (NIH). NIH.gov. 17 March 2020. Archived from the original on 23 March 2020. Retrieved 4 May 2020.
  4. - Zimmer C (26 February 2021). "The Secret Life of a Coronavirus - An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don't quite know what to make of it". Archived from the original on 27 February 2021. Retrieved 28 February 2021.
  5. -Wong G, Bi YH, Wang QH, Chen XW, Zhang ZG, Yao YG (May 2020). "Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?". Zoological Research. 41 (3): 213–219. doi:10.24272/j.issn.2095-8137.2020.031. PMC 7231470. PMID 32314559.
  6. - "WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020". World Health Organization (WHO) (Press release). 11 March 2020. Archived from the original on 11 March 2020. Retrieved 12 March 2020.
  7. -World Health Organization. Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care. Geneva: World Health Organization; 2014 Available from:
  8. https://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_eng.pdf?sequence=1
  9. -Liu J, Liao X, Qian S et al. Community transmission of severe acute respiratory syndrome coronavirus 2,Shenzhen, China, 2020. Emerg Infect Dis 2020 doi.org/10.3201/eid2606.200239
  10. -Ong SW, Tan YK, Chia PY, Lee TH, Ng OT, Wong MS. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020 Mar 4 (Epub ahead of print).
  11. - Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, Marr LC (August 2021). "Airborne transmission of respiratory viruses". Science. 373 (6558). Bibcode:2021Sci...373.....W. doi:10.1126/science.abd9149. PMID 34446582.
  12. -He, Xi; Lau, Eric H. Y.; Wu, Peng; Deng, Xilong; Wang, Jian; Hao, Xinxin; Lau, Yiu Chung; Wong, Jessica Y.; Guan, Yujuan; Tan, Xinghua; Mo, Xiaoneng; Chen, Yanqing; Liao, Baolin; Chen, Weilie; Hu, Fengyu; Zhang, Qing; Zhong, Mingqiu; Wu, Yanrong; Zhao, Lingzhai; Zhang, Fuchun; Cowling, Benjamin J.; Li, Fang; Leung, Gabriel M. (September 2020). "Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19". Nature Medicine. 26 (9): 1491–1493. doi:10.1038/s41591-020-1016-z.
  13. -Communicable Diseases Network Australia. "Coronavirus Disease 2019 (COVID-19): CDNA National Guidelines for Public Health Units". 5.1. Communicable Diseases Network Australia/Australian Government Department of Health.
  14. "Clinical Questions about COVID-19: Questions and Answers". Centers for Disease Control and Prevention. 4 March 2021.
  15. -"Scientific Brief: SARS-CoV-2 Transmission". Centers for Disease Control and Prevention. 7 May 2021. Retrieved 8 May 2021.
  16. - Liu T, Gong D, Xiao J, Hu J, He G, Rong Z, Ma W (October 2020). "Cluster infections play important roles in the rapid evolution of COVID-19 transmission: A systematic review". International Journal of Infectious Diseases. 99: 374–380. doi:10.1016/j.ijid.2020.07.073. PMC 7405860. PMID 32768702.
  17. -Meyerowitz EA, Richterman A, Gandhi RT, Sax PE (January 2021). "Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors". Annals of Internal Medicine. 174 (1): 69–79. doi:10.7326/M20-5008. ISSN 0003-4819. PMC 7505025. PMID 32941052.
  18. -Andersen, K.G.; Rambaut, A.; Lipkin, W.I.; Holmes, E.C.; Garry, R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020, 26, 450–452.
  19. -Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23.
  20. -F.A. Rabi, M.S. Al Zoubi, G.A. Kasasbeh, D.M. Salameh, A.D. Al-Nasser SARS-CoV-2 and Coronavirus disease 2019: what we know so far Journal, 9 (2020).
  21. -W. Wang, J. Tang, F. Wei Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China J. Med. Virol., 92 (2020), pp. 441-447,
  22. -Andrada Tanasa Ingrid, Carmen Manciuc, Alexandru Carauleanu, Dan Bogdan Navolan, Roxana Elena Bohiltea, Dragos Nemescu. Anosmia and Ageusia Associated With Corona Virus Infection (COVID-19)- What Is Known? (2020), pp. 2344-2347
  23. -C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet, 395 (2020), pp. 497-506, 10.1016/S0140-6736(20)30183-5
  24. -L.T. Phan, T.V. Nguyen, Q.C. Luong, H.T. Nguyen, H.Q. Le, T.T. Nguyen, T.M. Cao, Q.D. Pham Importation and human-to-human transmission of a novel coronavirus in Vietnam N. Engl. J. Med., 382 (2020), pp. 872-874, 10.1056/NEJMc2001272.
  25. -"Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
  26. - Oran, Daniel P., and Eric J. Topol. “Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.” Annals of Internal Medicine. vol. 173,5 (2020): 362-367. doi:10.7326/M20-3012 PMID 32491919 Retrieved 14 January 2021.
  27. - Furukawa NW, Brooks JT, Sobel J (July 2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerging Infectious Diseases. 26 (7). doi:10.3201/eid2607.201595. PMC 7323549. PMID 32364890.
  28. -Gandhi RT, Lynch JB, Del Rio C (October 2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. 383 (18): 1757–1766. doi:10.1056/NEJMcp2009249. PMID 32329974.
  29. -Byrne, Andrew William; McEvoy, David; Collins, Aine B.; Hunt, Kevin; Casey, Miriam; Barber, Ann; Butler, Francis; Griffin, John; Lane, Elizabeth A.; McAloon, Conor; O'Brien, Kirsty (1 August 2020). "Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases". BMJ Open. 10 (8): e039856. doi:10.1136/bmjopen-2020-039856. ISSN 2044-6055. PMID 32759252.
  30. -X.Y. Ge, J.L. Li, X. Lou Yang, A.A. Chmura, G. Zhu, J.H. Epstein, J.K. Mazet, B. Hu, W. Zhang, C. Peng, Y.J. Zhang, C.M. Luo, B. Tan, N. Wang, Y. Zhu, G. Crameri, S.Y. Zhang, L.F. Wang, P. Daszak, Z.L. Shi Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
  31. Nature, 503 (2013), pp. 535-538, 10.1038/nature12711
  32. -X. Zou, K. Chen, J. Zou, P. Han, J. Hao, Z. Han Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Journal. (2020), 10.1007/s11684-020-0754-0
  33. -"Novel coronavirus structure reveals targets for vaccines and treatments". National Institutes of Health (NIH). 2 March 2020. Archived from the original on 1 April 2020. Retrieved 3 April 2020.
  34. -Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. (March 2020). "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation". Science. 367 (6483): 1260–1263. Bibcode:2020Sci...367.1260W. doi:10.1126/science.abb2507. PMC 7164637. PMID 32075877.
  35. -Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res 2019;105:93–116.
  36. -Tortorici MA, Walls AC, Lang Y, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol 2019;26:481–9.
  37. -Walls AC, Xiong X, Park Y-J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 2019;176:1026–39.
  38. -Abdul Mannan Baig, Erin C. Sanders Potential neuroinvasive pathways of SARS-CoV-2: deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19)J. Med. Virol., 90 (2020), pp. 1845-1857
  39. -Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020 doi: 10.1016/S2468-1253(20)30048-0. published online Feb 19.
  40. -Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 doi: 10.1001/jama.2020.1585. published online Feb 7.
  41. -Hoffmann, M, Kleine-Weber, H, Schroeder, S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271--280.e8.
  42. -Liu, F, Long, X, Zou, W, et al. Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection. medrxiv Preprint 3 March 2020: 2020.2002. 2028.20029181. DOI: 10.1101/2020.02.28.20029181.
  43. -Chai, X, Hu, L, Zhang, Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv Preprint 4 February 2020: 2020.2002.2003.931766. DOI: 10.1101/2020.02. 03.931766.
  44. -Fan, Z, Chen, L, Li, J, et al. Clinical Features of COVID-19 related liver damage. medRxiv Preprint 28 February 2020: 2020.2002.2026.20026971. DOI: 10.1101/2020.02.26.20026971.
  45. -Jamwal S, Gautam A, Elsworth J, et al. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sci 2020;257:118105.
  46. -Zhang, C, Shi, L, Wang, FS. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 2020; 5: 428--430.
  47. -Zhao, B, Ni, C, Gao, R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver organoids. biorxiv Preprint 17 March 2020: 2020.2003.2016.990317. DOI: 10.1101/2020.03.16. 990317.
  48. -McDonald, B, Kubes, P. Innate immune cell trafficking and function during sterile inflammation of the liver. Gastroenterology 2016; 151: 1087–1095.
  49. -Li, L, Li, S, Xu, M, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv Preprint 10 March 2020: 2020.2002. 2028.20028514. DOI: 10.1101/2020.02.28.20028514.
  50. -S Seo, MJ Silverberg, LB Hurley, et al. Prevalence of spontaneous clearance of hepatitis C virus infection doubled from 1998 to 2017 Clin Gastroenterol Hepatol, 18 (2) (2020), pp. 511-513, 10.1016/j.cgh.2019.04.035
  51. -World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed May 17, 2020.
  52. -Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.
  53. -Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–637.
  54. -Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181: 271-280. :e8.
  55. -Esumi M, Ishibashi M, Yamaguchi H, Nakajima S, Tai Y, Kikuta S, Sugitani M, Takayama T, Tahara M, Takeda M, Wakita T. Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection. Hepatology. 2015;61:437–446.
  56. -Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415–423.
  57. -Hisada M, Chatterjee N, Kalaylioglu Z, Battjes RJ, Goedert JJ. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology. 2005;42:1446–1452.
  58. -Thurairajah P, Khanna A, Mutimer D. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J Viral Hepat 2010 Feb 1;17 (2):123-9) J Viral Hepat. 2011;18:820.
  59. -Hofmann SR, Ettinger R, Zhou YJ, Gadina M, Lipsky P, Siegel R, Candotti F, O'Shea JJ. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol. 2002;2:495–506.
  60. -Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–1754.
  61. -Wang, JT, Sheng, WH, Fang, CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10: 818–824.
  62. -Guan, WJ, Ni, ZY, Hu, Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. Epub ahead of print 28 February 2020. DOI: 10.1056/NEJMoa2002032.
  63. -Li, L, Li, S, Xu, M, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv Preprint 10 March 2020: 2020.2002. 2028.20028514. DOI: 10.1101/2020.02.28.20028514.
  64. -Chen, N, Zhou, M, Dong, X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507–513.
  65. -Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477–487.
  66. -World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization, 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed May 17, 2020.
  67. -Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008;134:1699–1714.
  68. -Gadotti AC, de Castro Deus M, Telles JP, Wind R, Goes M, Garcia Charello Ossoski R, de Padua AM, de Noronha L, Moreno-Amaral A, Baena CP, Tuon FF. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171.
  69. -Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol.
  70. -Barone M, Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, Cortese F, Gesualdo M, Brunetti N, Di Leo A, Scicchitano P, Ciccone MM. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol Res Pract. 2015;2015:682174.
  71. -Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46–64.
  72. -Ronderos Botero DM, Omar AMS, Sun HK, Mantri N, Fortuzi K, Choi Y, Adrish M, Nicu M, Bella JN, Chilimuri S. COVID-19 in the Healthy Patient Population: Demographic and Clinical Phenotypic Characterization and Predictors of In-Hospital Outcomes. Arterioscler Thromb Vasc Biol. 2020;40:2764–2775.